Navigation Links
Study shows new treatment strategy effective for certain lung cancers
Date:3/10/2011

New Orleans, LA LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients. Dr. Cataldo, a Clinical Assistant Professor of Medicine at LSU Health Sciences Center New Orleans School of Medicine, practicing at LSU's Earl K. Long Medical Center and Hematology-Oncology Clinic in Baton Rouge, and his colleagues say these drugs should be considered as a first-line treatment in people who are known to carry an Epidermal Growth Factor Receptor (EGFR) mutation. The paper is published in the March 10, 2011 issue of the New England Journal of Medicine.

The drugs, Erlotinib and Gefitinib, which are in a class of highly-specific small molecule tyrosine kinase inhibitors, work by blocking the activation of EGFR which is involved in cell survival and growth, as well as the development of a nourishing blood supply and metastasis.

"Targeting the genetic mutation contributing to the development of the cancer, this class of drugs produced a response rate that exceeded 70% in these patients," notes Dr. Cataldo.

The drugs, taken by mouth, also had fewer side effects. Unlike traditional cytotoxic agents, Erlotinib and Gefitinib do not typically cause myelosuppression, neuropathy, alopecia, or severe nausea.

Lung cancer, the leading cause of cancer-related death worldwide, accounted for an estimated 157,300 deaths in the United States in 2010. Approximately 85 to 90% of all cases of lung cancer are nonsmall-cell lung cancer (NSCLC) which is also associated with smoking. Advanced-stage NSCLC is currently considered an incurable disease for which standard chemotherapy provides marginal improvement in overall survival at the expense of substantial morbidity and mortality. Furthermore, less than 30% of patients with metastatic NSCLC have a response to platinum-based chemotherapy, the most commonly used initial treatment in this stage of the disease. Even with the addition of newer agents, such as bevacizumab, to chemotherapy, the median overall survival of patients with metastatic NSCLC remains approximately 1 year, and only 3.5% of patients with metastatic NSCLC survive 5 years after diagnosis.

"The EGFR mutation is just one of the mutations associated with non-small-cell lung cancer," says Dr. Cataldo. "These results also provide a model for identifying others, which we are currently pursuing. Treatment targeting the causes of this cancer will not only improve quality of life, but may also improve survival of this devastating disease."

The University of Texas the University of Texas M.D. Anderson Cancer Center, and Montefiore Medical Center, Albert Einstein College of Medicine also participated in the review.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. Study finds usage of, recommendations for supplements common within various physician specialties
2. Study provides explanation for connection between low birth weight and obesity later in life
3. New UF study shows some sharks follow mental map to navigate seas
4. Study shows how plants sort and eliminate genes over millennia
5. MBARI and Monterey Bay National Marine Sanctuary to study effects of shipping containers lost at sea
6. Rensselaer professor utilizing New York state grant to study adult stem cells
7. Study analyzes role of PARP enzyme in eukaryotes
8. Fossil bird study describes ripple effect of extinction in animal kingdom
9. University of Missouri researcher study provides insight into how corn makes hormones
10. Rainwater harvest study finds roofing material affects water quality
11. A study reveals the keys to the locomotion of snails
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2016)... Kingdom , Jan. 8, 2016   Bruin Biometrics, ... today announced the closing of a $9 million financing. The ... the financing will be used to accelerate the commercialization of ... early-stage pressure ulcers. United Kingdom ... Mark approval. The device,s introduction has been met with enthusiasm ...
(Date:1/7/2016)... , Jan. 7, 2016 Various factors ... biopharmaceutical products such as biologics and biosimilars. Some ... reduce healthcare expenditure, growing demand for cost-effective alternatives, ... population. Biosimilars are similar versions of their corresponding ... to their quality, safety, and efficacy. The global ...
(Date:1/6/2016)... , Jan. 6, 2016 Based ... market, Frost & Sullivan recognizes MorphoTrak, LLC, a ... North American Frost & Sullivan Company of the ... fingerprint scanning technology, Morpho Wave™ , has consolidated ... the fingerprint biometrics market. Morpho Wave is ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... ... February 03, 2016 , ... ... and Unix visualization solutions today announced the addition of a powerful “Session Preview” ... to see the current state of the remote Linux desktop or other applications ...
(Date:2/3/2016)... , Feb. 3, 2016  Silk Therapeutics, Inc., today announced ... Silk Therapeutics has now raised a total of $10.25 million ... the company. The Series A2 round was led by existing ... , with participation from new investors Lear Corporation and Highland ... Roy P. Disney ; Richard Sackler , MD, with ...
(Date:2/3/2016)... NY (PRWEB) , ... February 03, 2016 , ... ... new products to aid in the rapid development and ongoing quality control of ... Zika Virus outbreak is extremely high,” Dr. Gregory R. Chiklis, President and CEO ...
(Date:2/3/2016)... (PRWEB) , ... February 03, 2016 , ... ... silicon (Si) and InGaAs chips and wafers, and InP epi wafers based in ... from silicon detectors–including photodiodes, photo transistors, and Avalanche photodiodes–to Si and InGaAs PIN ...
Breaking Biology Technology: